Avant Diagnostics Simultaneously Completes Acquisitions of Amarantus Diagnostics and Theranostics Health

Avant Diagnostics, Inc. (OTCQB:  AVDX), an innovative molecular diagnostics company, today announced it has completed the acquisition of Amarantus Diagnostics, Inc., a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc. (OTCQX:  AMBS) and the business of Theranostics Health, Inc.

To read the full press release: Avant DX acquires Amarantus DX and Theranostics Health

Dr. O’Shaughnessy on Using Phosphoprotein Assays for Treatment Decision-Making for Breast Cancer

Joyce A. O’Shaughnessy, MD, of the Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses the use of phosphoprotein analysis in decision-making for triple negative breast cancer patients.  She highlights a subset of triple negative breast cancer patients  with elevated phospho-EGFR and activated downstream signaling pathways, as determined by proteomic analysis, who responded to anti-EGFR directed therapies.

View Dr. O’Shaughnessy’s video discussion at OncLive.                              OncLive_reduced

To learn more about phosphoprotein testing of breast cancer using the TheraLink® Assay for Breast Cancer or to order a test.

Theranostics Health Awarded California Clinical Laboratory License

Theranostics Health announced today that its CAP-CLIA laboratory has been awarded the California Clinical Laboratory License from the California Department of Health that will allow it to begin offering TheraLink® Assay analysis services to cancer patients in the State of California.

To read the press release: Theranostics Health CA Clinical Lab Permit

Theranostics Health Presents TheraLink® Assay for Breast Cancer at Biomarker World Congress



Biomarker World Congress 2015
2:50 pm, Tuesday May 5, 2015
Loews Philadelphia Hotel
Philadelphia, PA


Glenn Hoke, Ph.D., Executive Vice President and COO, is providing a presentation on the TheraLink®Assay for Breast Cancer titled “A novel Phospho-Proteomic Diagnostic for Patient Stratification and Therapy Selection for Breast Cancer” at the Biomarker World Congress.







Theranostics Health Announces Agreements with Avera Health to Assess and Develop TheraLink® Assay Technology

Theranostics Health, Inc., announced today a series of agreements to expand on current research and commercial collaborations with Avera Health to assess the TheraLink® Assay technologies as a proteomic-based personalized medicine tool in breast cancer, and to help explore its potential utility in a number of other key cancers.

To read more: Avera Health TheraLink® Technology Collaboration